Gland Pharma Limited Gland Pharma Limited

Gland Pharma Limited

GLAND

Rank in Stocks #3235
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Share Price
$32.78
Market Cap
$5.41B
Change (1 day)
-1.65%
Change (1 year)
50.07%
Country
IN
Trade Gland Pharma Limited (GLAND)

Category

Healthcare
P/S ratio for Gland Pharma Limited (GLAND)
P/S ratio as of October 2026 TTM: 7.47
According to Gland Pharma Limited latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.47. At the end of 2024 the company had a P/S ratio of 5.27.
P/S ratio history for Gland Pharma Limited from 2017 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 7.47 63.72%
2025 4.56 -13.61%
2024 5.27 -9.26%
2023 5.81 -52.56%
2022 12.25 7.08%
2021 11.44 4.38%
2020 10.96 -26.45%
2019 14.91 -20.73%
2018 18.80 -1.35%
2017 19.06 0.00%
P/S ratio for similar companies or competitors